Annual report
9158.TEDINET S100YKO7
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 147
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥54.4bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥47.0bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥33.0bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥35.2bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥35.3bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥5.8bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥5.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.1bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥2.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥2.7bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥97.9bn | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥85.2bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥62.8bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥39.8bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥34.5bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥63.9bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥54.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥34.0bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥30.3bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.0bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥33.4bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥29.7bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥27.3bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥11.7bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥9.5bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥15.8bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥8.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥4.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥5.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.2bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥3.4bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥4.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥14.7bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥6.7bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥6.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥14.4bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥4.0bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥4.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥97.35 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥106.81 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥93.99 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥113.9 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥97.35 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥106.81 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥93.99 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥113.9 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,139.32 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,012.38 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥931.79 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥533.1 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥453.12 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 34.1% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 34.8% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 43.5% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 29.4% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.4% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 9.0% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.3% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 22.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 38.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 5,740 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 5,145 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,743 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 2,994 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 2,470 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥7.4bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥7.8bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥14.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥15.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.6bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥2.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.3bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.4bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥949m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥1.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥65.8bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥56.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥45.5bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥28.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.4bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥32.6bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥24.4bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥23.5bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥22.3bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥8.1bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.4bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.9bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥32.38 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.63 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.01 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.21 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.53 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥822.07 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥797.1 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥759.3 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥365.69 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥335.57 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.0% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 29,990,400 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 29,990,400 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 29,990,400 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 113,152 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 416 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 467 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 434 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 423 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 374 | at 2022-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 63
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 3 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2026-03-31 | ¥148m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥148m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥0 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥27m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥475m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥475m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥933m |
| Hospicereportable segment | employees | at 2026-03-31 | 2335 pure |
| Hospicereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥16.7bn |
| Hospicereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥16.7bn |
| Hospicereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥980m |
| In Home Nursingreportable segment | employees | at 2026-03-31 | 1647 pure |
| In Home Nursingreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥12.9bn |
| In Home Nursingreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥12.9bn |
| In Home Nursingreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥10m |
| In Home Nursingreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| Medical Care Residencereportable segment | employees | at 2026-03-31 | 858 pure |
| Medical Care Residencereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥7.7bn |
| Medical Care Residencereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥7.7bn |
| Medical Care Residencereportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥262m |
| Medical Institutionreportable segment | employees | at 2026-03-31 | 739 pure |
| Medical Institutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥17.3bn |
| Medical Institutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥16.8bn |
| Medical Institutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥465m |
| Medical Institutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥4.6bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥54.7bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥54.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥475m |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥54.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥54.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥475m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥6.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥120m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥120m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥55m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥314m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥314m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥834m |
| Hospicereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Hospicereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Hospicereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| In Home Nursingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| In Home Nursingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| In Home Nursingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| In Home Nursingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Medical Care Residencereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Care Residencereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Care Residencereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥299m |
| Medical Institutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥17.6bn |
| Medical Institutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥17.3bn |
| Medical Institutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| Medical Institutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥47.2bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥46.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥47.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.2bn |
| Medical Institutionreportable segment | employees | at 2026-03-31 | 258 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,860
| Item | Context | Value | Unit |
|---|---|---|---|
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0668 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0220 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.6272 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.1655 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0002 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.1183 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 18600000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.6345 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 1820000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0621 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 960600 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0328 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 870400 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0297 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 817000 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0279 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 498400 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0170 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 414000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0141 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 383600 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0131 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 325000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0111 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 300600 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0103 | |
| Number of shares held | CurrentYearInstant | 24989600 | |
| Shareholding ratio | CurrentYearInstant | 0.8524 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 675000 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 29309100 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 293091 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 6300 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 29990400 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 293091 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 675000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 675000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0225 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 675000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 675000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0225 | |
| Number of male directors and other officers | FilingDateInstant | 5 | |
| Number of female directors and other officers | FilingDateInstant | 2 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.286 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |